AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open

Yazar: Zielinski, Christoph C, Pinto, Carmine
Yayımlandı ESMO Open (2016)

ESMO Open—Cancer Horizons and the future of oncology

Yazar: Zielinski, Christoph C
Yayımlandı ESMO Open (2016)

CSCO joins ESMO Open—Cancer Horizons

Yazar: Zielinski, Christoph C, Wu, Yi-Long
Yayımlandı ESMO Open (2016)

ESMO Open: news in breast cancer 2019

Yazar: Lambertini, Matteo
Yayımlandı ESMO Open (2020)

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)

Yazar: Ohe, Yuichiro, Zielinski, Christoph
Yayımlandı ESMO Open (2017)

ESMO Open special series on new emerging targets in cancer immunotherapy

Yazar: Lambertini, Matteo
Yayımlandı ESMO Open (2020)

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment

Yazar: Morgan, Gilberto, Preusser, Matthias, Zielinski, Christoph
Yayımlandı ESMO Open (2020)

One year of ESMO Open: Cancer Horizons—where are we going from here?

Yazar: Zielinski, Christoph
Yayımlandı ESMO Open (2017)

Plasmodesmata. A Not So Open-and-Shut Case

Yazar: Oparka, K. J., Roberts, A. G.
Baskı/Yayın Bilgisi 2001

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

Yazar: Preusser, Matthias
Yayımlandı ESMO Open (2019)

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

Yazar: Burke, Patrick W, Hoelzer, Dieter, Park, Jae H, Schmiegelow, Kjeld, Douer, Dan
Yayımlandı ESMO Open (2020)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

Yazar: Banerjee, Susana, Gonzalez-Martin, Antonio, Harter, Philipp, Lorusso, Domenica, Moore, Kathleen N, Oaknin, Ana, Ray-Coquard, Isabelle
Yayımlandı ESMO Open (2020)

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

Yazar: Awada, Ahmad, Gligorov, Joseph, Jerusalem, Guy, Preusser, Matthias, Singer, Christian, Zielinski, Christoph
Yayımlandı ESMO Open (2019)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

Yazar: Lambertini, Matteo, Preusser, Matthias, Zielinski, Christoph C
Yayımlandı ESMO Open (2019)

Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

Yazar: Lamarca, A., Foster, L., Satyadas, T., Siriwardena, A., Valle, J.W.
Yayımlandı ESMO Open (2021)

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

Yazar: Peleg Hasson, S., Brezis, M.R., Shachar, E., Shachar, S.S., Wolf, I., Sonnenblick, A.
Yayımlandı ESMO Open (2021)

Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]

Yazar: Shi, L., Xu, C., Ma, Y., Ou, Q., Wu, X., Lu, S., Shao, Y., Guo, R., Kong, J.
Yayımlandı ESMO Open (2021)

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue...

Yazar: Lee, R.J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., Aung, T., Banfill, K., Baxter, M., Boyce, H., Brearton, G., Copson, E., Dickens, E., Eastlake, L., Gomes, F., Hague, C., Harrison, M., Horsley, L., Huddar, P., Hudson, Z., Khan, S., Khan, U.T., Maynard, A., McKenzie, H., Palmer, D., Robinson, T., Rowe, M., Thomas, A., Tweedy, J., Sheehan, R., Stockdale, A., Weaver, J., Williams, S., Wilson, C., Zhou, C., Dive, C., Cooksley, T., Palmieri, C., Freitas, A., Armstrong, A.C.
Yayımlandı ESMO Open (2021)

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO...

Yazar: Banna, G.L., Cortellini, A., Cortinovis, D.L., Tiseo, M., Aerts, J.G.J.V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., Berardi, R., Morabito, A., Genova, C., Mazzoni, F., Di Noia, V., Signorelli, D., Gelibter, A., Macerelli, M., Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Montrone, M., Citarella, F., Marco, R., Cantini, L., Nigro, O., D'Argento, E., Buti, S., Minuti, G., Landi, L., Guaitoli, G., Lo Russo, G., De Toma, A., Donisi, C., Friedlaender, A., De Giglio, A., Metro, G., Porzio, G., Ficorella, C., Addeo, A.
Yayımlandı ESMO Open (2021)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]

Yazar: De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Caputo, R., Cianniello, D., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., Arpino, G.
Yayımlandı ESMO Open (2021)